Research Progress on the Mitochondrial Pyruvate Carrier（MPC）

doi:10.13560/j.cnki.biotech.bull.1985.2018-0926

Abstract

Abstract: The mitochondrial pyruvate carrier（MPC）in mitochondrial inner membrane transports the pyruvate from the cytoplasm to the mitochondrial matrix. The pyruvate involves in the tricarboxylic acid cycle,gluconeogenesis,and the metabolic processes such as lipids and amino acids,which provides energy to the body. Therefore,MPC regulates energy metabolism by controlling the flux of pyruvate into the mitochondrial matrix. This paper summarized the biological characteristics of MPC and its relationship with metabolic diseases. It has been found that inhibition of MPC activity may lead to a decrease in hepatic gluconeogenesis,which in turn affects glucose homeostasis and reduces the incidence of typeⅡdiabetes. It also prevents the transmission of insulin signaling by affecting glucose-stimulated insulin secretion,resulting in that body is not sensitive to external glucose uptake;thus the MPC complex is essential to the glucose homeostasis. However,the activity of MPC is inhibited in most cancer tissues,specifically activating the MPC function should be conducted to enhance its aerobic metabolism,to inhibit that the cancer cells use lactic acid to supply energy and subsequently to hinder the proliferation of cancer cells. MPC is considered to be an initial point for studying energy metabolism regulation and potential therapeutic target sites,and also provides new therapeutic ideas for studying metabolic diseases such as obesity,diabetes and cancers.

Key words: pyruvate, the mitochondrialpyruvate carrier, energy metabolism

XIE Wen-ya, ZOU Shi-ying, Gao Ru-xin, HE Xiao-yun. Research Progress on the Mitochondrial Pyruvate Carrier（MPC）[J]. Biotechnology Bulletin, 2019, 35(7): 196-201.

References

[1] Papa S, Francavilla A, Paradies G, et al.The transport of pyruvate in rat liver mitochondria[J]. FEBS Letters, 1971, 12(5):285-288.
[2] Halestrap AP.The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors[J]. Biochemical Journal, 1975, 148(1):85-96.
[3] Brivet M, Garcia CAS, Dumez Y, et al.Impaired mitochondrial pyruvate importation in a patient and a fetus at risk[J]. Molecular Genetics & Metabolism, 2003, 78(3):186-192.
[4] Bricker DK, Taylor EB, Schell JC, et al.A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans[J]. Science, 2012, 337(6090):96-100.
[5] Herzig S, Martinou JC.Identification and functional expression of the mitochondrial pyruvate carrier[J]. Science, 2012, 337(6090):93-96.
[6] Utter MF, Keech DB. Formation of oxaloacetate from pyruvate and carbon dioxide[J]. J Biol Chem, 1960, 235:PC17.
[7] Vacanti NM, Divakaruni AS, Green CR, et al.Regulation of substrate utilization by the mitochondrial pyruvate carrier[J]. Molecular Cell, 2014, 56(3):425-435.
[8] Vanderperre B, Herzig S, Krznar P, et al.Embryonic lethality of mitochondrial pyruvate carrier 1 deficient mouse can be rescued by a ketogenic diet[J]. PLoS Genetics, 2016, 12(5):e1006056.
[9] Li X, Li Y, Han G, et al.Establishment of mitochondrial pyruvate carrier 1(MPC1)gene knockout mice with preliminary gene function analyses[J]. Oncotarget, 2016, 7(48):79981-79994.
[10] Zou S, Lang T, Zhang B, et al.Fatty acid oxidation alleviates the energy deficiency caused by the loss of MPC1 in MPC1+/- mice[J]. Biochem Biophys Res Commun, 2018, 495(1):1008-1013.
[11] Owen OE, Kalhan SC, Hanson RW.The key role of anaplerosis and cataplerosis for citric acid cycle function[J]. J Biol Chem, 2002, 277(34):30409-30412.
[12] Vigueira PA, Mccommis KS, Schweitzer GG, et al.Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion[J]. Cell Reports, 2014, 7(6):2042-2053.
[13] Gray LR, Sultana MR, Rauckhorst AJ, et al.Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis[J]. Cell Metabolism, 2015, 22(4):669-681.
[14] Mccommis KS, Chen Z, Fu X, et al.Loss of mitochondrial pyruvate carrier 2 in liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling[J]. Cell Metabolism, 2015, 22(4):682-694.
[15] Rauckhorst AJ, Gray LR, Sheldon RD, et al.The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity[J]. Molecular Metabolism, 2017, 6(11):1468-1479.
[16] Duan SZ, Ivashchenko CY, Russell MW, et al.Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice[J]. Circulation Research, 2005, 97(4):372-379.
[17] Zhang H, Zhang A, Kohan DE, et al.Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(26):9406-9411.
[18] Mccommis KS, Hodges WT, Brunt EM, et al.Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis[J]. Hepatology, 2017, 65(5):1543-1556.
[19] Guan YF, Hao C, Cha DR, et al.Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption[J]. Nature Med, 2005, 11(8):861.
[20] Chen Z, Vigueira PA, Chambers KT, et al.Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione[J]. J Biol Chem, 2012, 287(28):23537-23548.
[21] Vigueira PA, Mccommis KS, Hodges WT, et al.The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism[J]. Experimental Physiology, 2017, 102(8):985-999.
[22] Vacanti NM, Divakaruni AS, Green CR, et al.Regulation of substrate utilization by the mitochondrial pyruvate carrier[J]. Molecular Cell, 2014, 56(3):425-435.
[23] Colca JR, Mcdonald WG, Cavey GS, et al.Identification of a mitochondrial target of thiazolidinedione insulin sensitizers(mTOT)—relationship to newly identified mitochondrial pyruvate carrier proteins[J]. PLoS One, 2013, 8(5):e61551.
[24] 赵凤艳, 屈艺, 张林, 等. Aurora A表达对人前列腺癌细胞生物学行为的影响[J]. 四川大学学报:医学版, 2007, 38(2):302-305.
[25] Schell JC, Olson KA, Jiang L, et al.A role for the mitochondrial pyruvate carrier as a repressor of the warburg effect and colon cancer cell growth[J]. Molecular Cell, 2014, 56(3):400-413.
[26] Cai H, Kumar N, Ai N, et al.Progenetix:12 years of oncogenomic data curation[J]. Nucleic Acids Research, 2014, 42(Database issue):1055-1062.
[27] Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, et al.SurvExpress:an online biomarker validation tool and database for cancer gene expression data using survival analysis[J]. PLoS One, 2013, 8(9):e74250.
[28] Cerami E, Gao J, Dogrusoz U, et al.The cBio Cancer genomics portal:an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discovery, 2012, 2(5):401-404.
[29] Gao J, Aksoy BA, Dogrusoz U, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Science Signaling, 2013, 6(269):pl1.
[30] Network CGA.Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(7407):330-337.
[31] Handschin C, Spiegelman BM.Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism[J]. Endocrine Reviews, 2006, 27(7):728-735.
[32] Girnun G.The diverse role of the PPARgamma coactivator 1 family of transcriptional coactivators in cancer[J]. Seminars in Cell & Developmental Biology, 2012, 23(4):381-388.
[33] Koh E, Kim YK, Shin D, et al. MPC1 is essential for PGC-1α-induced mitochondrial respiration and biogenesis[J]. Biochemical Journal, 2018, 475(10):BCJ20170967.
[34] 马向明. 线粒体丙酮酸载体与肝细胞肝癌患者预后的相关性研究[D]. 天津:天津医科大学, 2017.
[35] Morrison R, Schleicher SM, Sun Y, et al.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis[J]. Journal of Oncology, 2011(12):941876.
[36] Heddleston JM, Li Z, Lathia JD, et al.Hypoxia inducible factors in cancer stem cells[J]. British Journal of Cancer, 2010, 102(5):789-795.
[37] Defronzo RA, Abdul-Ghani M.Type 2 diabetes can be prevented with early pharmacological intervention[J]. Diabetes Care, 2011, 2(Suppl 2):202-209.
[38] Ryder REJ.Pioglitazone:an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes[J]. British Journal of Diabetes & Vascular Disease, 2011, 11(3):113-120.
[39] Corbet C, Bastien E, Draoui N, et al.Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects[J]. Nature Communications, 2018, 9(1):1208.